Aristotle Capital Boston’s Chemed CHE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20M | Sell |
52,811
-7,832
| -13% | -$3.35M | 1.24% | 22 |
|
|
2025
Q4 | $25.9M | Sell |
60,643
-3,449
| -5% | -$1.5M | 1.42% | 13 |
|
|
2025
Q3 | $28.7M | Buy |
64,092
+3,737
| +6% | +$1.69M | 1.48% | 17 |
|
|
2025
Q2 | $29.4M | Sell |
60,355
-4,748
| -7% | -$2.71M | 1.5% | 17 |
|
|
2025
Q1 | $40.1M | Sell |
65,103
-13,290
| -17% | -$7.55M | 2% | 9 |
|
|
2024
Q4 | $41.5M | Sell |
78,393
-9,038
| -10% | -$5.09M | 1.54% | 17 |
|
|
2024
Q3 | $52.5M | Sell |
87,431
-2,552
| -3% | -$1.45M | 1.74% | 10 |
|
|
2024
Q2 | $48.8M | Sell |
89,983
-3,770
| -4% | -$2.16M | 1.64% | 12 |
|
|
2024
Q1 | $60.2M | Sell |
93,753
-3,107
| -3% | -$1.89M | 1.83% | 10 |
|
|
2023
Q4 | $56.6M | Sell |
96,860
-4,452
| -4% | -$2.49M | 1.73% | 9 |
|
|
2023
Q3 | $52.7M | Sell |
101,312
-548
| -0.5% | -$285K | 1.7% | 8 |
|
|
2023
Q2 | $55.2M | Buy |
101,860
+2,368
| +2% | +$1.29M | 1.66% | 10 |
|
|
2023
Q1 | $53.5M | Buy |
99,492
+2,603
| +3% | +$1.33M | 1.65% | 9 |
|
|
2022
Q4 | $49.5M | Sell |
96,889
-2,665
| -3% | -$1.3M | 1.56% | 10 |
|
|
2022
Q3 | $43.5M | Sell |
99,554
-9,302
| -9% | -$4.47M | 1.47% | 10 |
|
|
2022
Q2 | $51.1M | Buy |
108,856
+3
| +0% | +$1.46K | 1.52% | 7 |
|
|
2022
Q1 | $55.1M | Sell |
108,853
-1,936
| -2% | -$928K | 1.39% | 13 |
|
|
2021
Q4 | $58.6M | Sell |
110,789
-4,013
| -3% | -$1.93M | 1.37% | 14 |
|
|
2021
Q3 | $53.4M | Sell |
114,802
-308
| -0.3% | -$145K | 1.25% | 16 |
|
|
2021
Q2 | $54.6M | Sell |
115,110
-6,887
| -6% | -$3.31M | 1.25% | 19 |
|
|
2021
Q1 | $56.1M | Sell |
121,997
-5,933
| -5% | -$2.91M | 1.25% | 21 |
|
|
2020
Q4 | $68.1M | Sell |
127,930
-20,805
| -14% | -$10.2M | 1.61% | 12 |
|
|
2020
Q3 | $71.4M | Buy |
148,735
+525
| +0.4% | +$258K | 2.07% | 2 |
|
|
2020
Q2 | $66.9M | Buy |
148,210
+13,723
| +10% | +$6.13M | 2.03% | 7 |
|
|
2020
Q1 | $58.3M | Buy |
134,487
+3,216
| +2% | +$1.44M | 2.49% | 2 |
|
|
2019
Q4 | $57.7M | Buy |
131,271
+2,978
| +2% | +$1.25M | 1.59% | 13 |
|
|
2019
Q3 | $53.6M | Sell |
128,293
-10,322
| -7% | -$4.21M | 1.57% | 11 |
|
|
2019
Q2 | $50M | Sell |
138,615
-3,065
| -2% | -$1.02M | 1.56% | 16 |
|
|
2019
Q1 | $45.3M | Buy |
141,680
+78,176
| +123% | +$24M | 1.51% | 14 |
|
|
2018
Q4 | $18M | Buy |
63,504
+9,812
| +18% | +$2.96M | 1.47% | 16 |
|
|
2018
Q3 | $17.2M | Sell |
53,692
-4,928
| -8% | -$1.57M | 1.26% | 23 |
|
|
2018
Q2 | $18.9M | Sell |
58,620
-50,941
| -46% | -$15.9M | 1.5% | 13 |
|
|
2018
Q1 | $29.9M | Buy |
109,561
+15,270
| +16% | +$4.05M | 1.41% | 16 |
|
|
2017
Q4 | $22.9M | Buy |
94,291
+21,630
| +30% | +$4.91M | 1.67% | 9 |
|
|
2017
Q3 | $14.7M | Buy |
72,661
+5,250
| +8% | +$1.03M | 1.31% | 19 |
|
|
2017
Q2 | $13.8M | Buy |
67,411
+11,682
| +21% | +$2.33M | 1.54% | 12 |
|
|
2017
Q1 | $10.2M | Buy |
55,729
+1,659
| +3% | +$289K | 1.36% | 20 |
|
|
2016
Q4 | $8.67M | Buy |
54,070
+8,646
| +19% | +$1.27M | 1.19% | 29 |
|
|
2016
Q3 | $6.41M | Buy |
45,424
+2,063
| +5% | +$287K | 1.14% | 33 |
|
|
2016
Q2 | $5.91M | Buy |
43,361
+1,342
| +3% | +$178K | 1.15% | 32 |
|
|
2016
Q1 | $5.69M | Buy |
42,019
+535
| +1% | +$72.3K | 1.14% | 30 |
|
|
2015
Q4 | $6.21M | Sell |
41,484
-7,052
| -15% | -$1.04M | 1.27% | 26 |
|
|
2015
Q3 | $6.48M | Buy |
48,536
+344
| +0.7% | +$48.2K | 1.58% | 17 |
|
|
2015
Q2 | $6.32M | Buy |
48,192
+7,820
| +19% | +$968K | 1.44% | 21 |
|
|
2015
Q1 | $4.82M | Buy |
40,372
+14,808
| +58% | +$1.64M | 1.5% | 18 |
|
|
2014
Q4 | $2.7M | Buy |
+25,564
| New | +$2.7M | 1.35% | 21 |
|
Other funds holding CHE
VPM
VCM
Aristotle Capital Boston's CHE Position: Q1 2026 in Review
Aristotle Capital Boston reduced its Chemed (CHE) stake by 13% in Q1 2026, selling an estimated $3.35M and leaving 52,811 shares worth $20M. The position accounts for 1.24% of the portfolio, ranked #22.
Aristotle Capital Boston first reported a position in CHE in Q4 2014 and has held it in 46 quarters since. The position peaked at $71.4M in Q3 2020. 488 funds tracked by Wall St. Rank hold CHE as of Q1 2026.
- Aristotle Capital Boston held 52,811 shares of Chemed worth $20M as of Q1 2026.
- Aristotle Capital Boston sold 7,832 Chemed shares in Q1 2026, an estimated $3.35M.
- Chemed made up 1.24% of Aristotle Capital Boston's portfolio in Q1 2026, its #22 holding.
- Aristotle Capital Boston first reported a position in Chemed in Q4 2014 and has held it in 46 quarters since.
- Aristotle Capital Boston's Chemed position peaked at $71.4M in Q3 2020.
- 488 funds tracked by Wall St. Rank held Chemed as of Q1 2026.
Based on Aristotle Capital Boston's 13F filing for Q1 2026, filed 15 May 2026.